|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 (a Fibrin Derived Peptide Bbeta15-42) on Ischemia Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The "F.I.R.E." Study
The purpose of the study is to evaluate whether FX06 is capable of limiting infarct size following balloon catheterization for acute myocardial infarction.
A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Measure the Effect of FX06 (a fibrin derived peptide Bß15-42) on Ischemia-Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The F.I.R.E.” Study - The F.I.R.E. Study
100 Clinical Results associated with FIBREX Medical, Inc.
0 Patents (Medical) associated with FIBREX Medical, Inc.
FX06 (fibrin-derived peptide Bbeta15-42) - A potential candidate for
myocardial reperfusion therapy
Author: Henning, Rainer ; Petzelbauer, Peter ; Zacharowski, Kai
A review.FX06 (fibrin derived peptide Bβ15-42) is a promising new drug candidate indicated for the prevention of reperfusion injury in patients undergoing primary percutaneous intervention (PCI) for acute myocardial infarction (AMI).This novel peptide has been shown to prevent myocardial reperfusion injury in a number of acute and chronic animal models for this disease when given as a single bolus injection at the time of reperfusion.FX06 has a novel mechanism of action: it is a competitive inhibitor of the binding of fibrin E1 fragments to vascular endothelial (VE)-cadherin.Through this inhibition, it potently blocks the transmigration of inflammatory leukocytes through the endothelial barrier and prevents the downstream release of tissue-damaging mediators.FX06 has proven safe in acute and subchronic toxicol. studies and recently entered clin. development.
100 Deals associated with FIBREX Medical, Inc.
100 Translational Medicine associated with FIBREX Medical, Inc.